Mechanism of Resistance to Amikacin and Kanamycin in Mycobacterium tuberculosis | Zendy

George Alangaden | Zendy; Barry N. Kreiswirth | Zendy; Arlette Aouad | Zendy; Minoo Khetarpal | Zendy; Felicitas R. Igno | Zendy; Soraya L. Moghazeh | Zendy; Elias K. Manavathu | Zendy; Stephen A. Lerner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mechanism of Resistance to Amikacin and Kanamycin in Mycobacterium tuberculosis

Author(s) -

George Alangaden,

Barry N. Kreiswirth,

Arlette Aouad,

Minoo Khetarpal,

Felicitas R. Igno,

Soraya L. Moghazeh,

Elias K. Manavathu,

Stephen A. Lerner

Publication year - 1998

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.42.5.1295

Subject(s) - kanamycin , amikacin , mycobacterium tuberculosis , microbiology and biotechnology , tuberculosis , mechanism (biology) , biology , medicine , antibiotics , virology , pathology , philosophy , epistemology

An A1400G mutation of the rrs gene was identified in Mycobacterium tuberculosis (MTB) strain ATCC 35827 and in 13 MTB clinical isolates resistant to amikacin-kanamycin (MICs, >128 microg/ml). High-level cross-resistance may result from such a mutation since MTB has a single copy of the rrs gene. Another mechanism(s) may account for high-level amikacin-kanamycin resistance in two mutants and lower levels of resistance in four clinical isolates, all lacking the A1400G mutation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research